Answers are grounded in this paper and cite their sources.
A novel sorbent hemoadsorption device for cytokine removal (CytoSorbents, USA) was developed and successfully tested in animal models of sepsis. The experience in the clinical setting is still limited to case reports. In this first clinical trial, we tested the hypothesis that treatment with sorbent hemoadsorption could safely and effectively reduce cytokines in septic patients with acute lung injury (ALI).
No takes yet. Share an insight, caveat, or question.
Schädler et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: